AgingResearch.NewsJoin free

Dewpoint Therapeutics

CompanyUnited States

Dewpoint Therapeutics develops 3 assets, the furthest in phase 1 (DPTX3186 in advanced solid tumor). Mostly small molecule acting on MYC; based in the United States.

3
Assets
Furthest stage
Phase 1
Raised
US$304.2m
0
Trials
0
Signals

Pipeline

3

  • DPTX3186

    Sequesters beta-catenin into inactive depot condensates, inhibiting beta-catenin and Wnt-pathway activity.

    Phase 1, Small molecule, advanced solid tumor, gastric cancer

  • MYC

    Dissolves oncogenic transcriptional MYC condensates, inhibiting MYC’s oncogenic functions.

    Preclinical, Small molecule, MYC, solid tumor

  • TDP-43

    Departitions pathological cytoplasmic TDP43 condensates and restores TDP-43 splicing across diverse ALS genotypes.

    Preclinical, Small molecule, ALS, related neurodegenerative diseases

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Funding rounds and grants3
  • People20
  • Similar companies6

Intelligence